Authors


Charles Benaiah

Latest:

Talk About Talk

Audio platforms provide new opportunities for pharma.


Kevin Troyanos

Latest:

Why Your Advertising Agency Should Be Your Analytics Partner

Brands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.


Jayachandra Reddy and Rishit Thakkar

Latest:

Navigating the Untapped NASH Market

A potential rush of treatment options on the horizon for non-alcoholic steatohepatitis will require skillful maneuvering in this likely lucrative but uncharted therapeutic market.




Jackie Ilacqua & Valerie Wriede

Latest:

The Rising Tide of Next Generation Cancer Treatments

The Ipsos Healthcare Oncology Centre of Excellence's Jackie Ilacqua & Valerie Wriede trace the evolution of cancer treatment and drill down into the latest developments currently redefining the landscape, together with those on the horizon.


Mariel Metcalfe

Latest:

NASH: Pointers for Pharma from the Patient Perspective

With the NASH pipeline filling up fast, Mariel Metcalfe looks at what pharma companies need to do to ensure their products do not end up as also-rans in this dynamic new market segment.



Adam Nelson

Latest:

How Pharmas, Payers, and Providers Can Meet the ‘Triple Aim’

Today’s model requires a fourth partner-the systems integrator



Bhaskar Sambasivan

Latest:

Rebooting Life Sciences with Digital

Mastering digital business strategies and tactics will enable life sciences companies to supercharge innovation and speed therapy discovery, patient centric-practices and improved health outcomes, writes Bhaskar Sambasivan.


MilliporeSigma

Latest:

e-Data and the Biopharmaceutical Supply Chain

MilliporeSigma’s Stephen Wing, head of Analytical and Logistical Services, discusses the ways in which digital transformation and data transparency dramatically enhance supply chains, and how manufacturers are using the company’s eMERGE™ platform to improve overall efficiencies.



Shelby Buettner

Latest:

When HIPAA Doesn’t Apply

Outlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.


Jennifer S. Geetter

Latest:

When HIPAA Doesn’t Apply

Outlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.


Brenda L. Gleason

Latest:

How Can We Be Healthcare Leaders Right Now?

Brenda Gleason discusses the current health policy landscape and how future pharmacists can be healthcare leaders during a lecture at University of North Carolina Eshelman School of Pharmacy.


Howard Pezim and Darren Raycroft

Latest:

Resilience in a Sea of Change: Ed Gudaitis, GM – Canada, Allergan

Ed Gudaitis Allergan VP and Country Manager, Canada, explains how embracing disruption is his secret to success.



John Maslowski

Latest:

Developing Drugs for Rare Diseases: Insights for Pharma Execs

This article explores the difficult nature of developing drugs for rare diseases and discusses what a pharmaceutical executive can actively do to help increase success.


Harriet Kozak

Latest:

Medical Marijuana: A Challenge to Traditional Pain Relief?

Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, but the future for this market is still uncertain, writes Harriet Kozak.


Kimberly E. White

Latest:

Engaging in Risk-Sharing Agreements with Providers

Before entering into risk-sharing agreements, manufacturers must understand the challenges and implications, writes Kimberly E. White.


IQVIA

Latest:

Global Real World Data Tour: 2024 Key Insights

Webinar Date/Time: Wednesday, October 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST


John Sattler

Latest:

Job Hunter Meet Headhunter (aka Executive Recruiter)

John Sattler offers some tips on engaging executive and professional recruiters.


John Reuland

Latest:

How HEOR Can Claim the Spotlight

If HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.


Craig Granowitz

Latest:

Pragmatic Therapy: Balancing Innovation, Cost, and Care

is spectacular science enough to guarantee success for new medicines?


Abigail Bernardi

Latest:

Multidisciplinary Care Teams: Challenge or Opportunity?

Abigail Bernardi explains how a better understanding of connections among practitioners on care teams helps sales reps build relationships while benefitting a company’s marketing efforts.


Robert Dumitrescu, Mithila Rajagopal, Eric Bachman, and Sarah Scalia

Latest:

QIDP: An Insufficient Policy?

The GAIN Act creates a process for the Qualified Infectious Disease Product (QIDP) designation, which provides a range of incentives for developing antimicrobial therapies for combating resistant organisms. But while the program has been successful in driving innovation, commercial viability remains a question.


Mark Bouch, Stephen Bungay, and David Roblin

Latest:

Taking Command of Strategy Execution

Mark Bouch, Stephen Bungay, and David Roblin outline how the technique of "mission command", a military approach to setting direction and executing strategy in the pharmaceutical industry, has developed over the last ten years.


Paul Meade and Mark Schoeman

Latest:

The Power of MSL Authenticity

Paul Meade and Mark Schoeman describe the determining factor driving effective relationships between medical science liaisons and key opinion leaders.


Steven Shill

Latest:

US Healthcare Could Be the Booster Shot That “Healthy China” Needs

The Chinese government's “Healthy China” plan presents an unprecedented opportunity for the US healthcare industry and its investors, writes Steven Shill.

© 2025 MJH Life Sciences

All rights reserved.